Manja
Manja Friese-Hamim, Moerfelden-Walldorf DE
Patent application number | Description | Published |
---|---|---|
20150031670 | CYCLIC AMIDES AS METAP-2 INHIBITORS - Compounds of the formula (I), in which R | 01-29-2015 |
20150044211 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS - A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with a compound selected from the group erlotinib, cetuximab, aflibercept, bevacizumab. | 02-12-2015 |
20150283137 | 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC) - 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of hepatocellular carcinoma (HCC). | 10-08-2015 |
20150297594 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor - A pharmaceutical composition comprising 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof and N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide or a pharmaceutically acceptable salt and/or solvate thereof. | 10-22-2015 |
Manja Gloser, Teutschenthal DE
Patent application number | Description | Published |
---|---|---|
20120301393 | MODIFIED UBIQUITIN PROTEINS HAVING A SPECIFIC BINDING ACTIVITY FOR THE EXTRADOMAIN B OF FIBRONECTIN - The present invention refers to novel recombinant proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B). Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. | 11-29-2012 |
20130011334 | MODIFIED UBIQUITIN PROTEINS HAVING A SPECIFIC BINDING ACTIVITY FOR THE EXTRADOMAIN B OF FIBRONECTIN - The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods. | 01-10-2013 |
20150183846 | HUMAN FUSION PROTEINS COMPRISING SINGLE CHAIN TNFALPHA AND TARGETING DOMAINS - The present invention relates to fusion proteins in which a biologically active moiety is linked to a targeting domain. The invention specifically concerns fusion proteins comprising single-chain (sc) TNFalpha monomers as biologically active moiety and a specific targeting domain, preferably fusion proteins comprising at least three scTNFalpha monomers and modified hetero-dimeric ubiquitin proteins with high affinity to target molecules (Affilin® molecules). The invention further relates to these fusion proteins for use in medicine, in particular in the treatment of cancer. The invention is further directed to pharmaceutical compositions comprising such fusion proteins in combination with chemotherapeutics agents. | 07-02-2015 |
Manja Gloser, Halle/saale DE
Patent application number | Description | Published |
---|---|---|
20140219959 | HUMAN FUSION PROTEINS COMPRISING INTERFERONS AND TARGETED MODIFIED UBIQUITIN PROTEINS - The present invention relates to fusion proteins in which a pharmaceutically active component is fused to an antibody mimetic. The invention specifically concerns fusion proteins comprising interferons or biologically active muteins thereof and modified hetero-dimeric ubiquitin proteins as specific targeting domain. The invention further relates to these fusion proteins for use in medicine, in particular for use in the treatment of cancer or infectious diseases. The invention is further directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with such fusion proteins, and in combination with cancer therapeutic agents. Moreover, the invention relates to a method for the generation of said fusion proteins. | 08-07-2014 |
Manja Greimeier, Mannheim DE
Patent application number | Description | Published |
---|---|---|
20150301182 | OPTICAL OBJECT-DETECTION DEVICE HAVING A MEMS AND MOTOR VEHICLE HAVING SUCH A DETECTION DEVICE - An optical object sensing device for a motor vehicle, having an emitter unit for emitting an emission light beam and having a receiver unit for receiving a reception light beam, and having an electronic evaluation device for detecting an object external to the vehicle in a vicinity of the motor vehicle as a function of the reception light beam. The emitter unit includes an emitter for generating the emission light beam, a controllable micromirror by which the emission light beam can be panned at least in a first panning direction, and an emission lens arranged behind the micromirror in the emission beam path, where at least along the first panning direction, the emission lens is configured as a concave-convex lens with a concavely curved surface, which faces towards the micromirror, and with a convexly curved surface. | 10-22-2015 |
Manja Kamprad, Leipzig DE
Patent application number | Description | Published |
---|---|---|
20080216182 | Animal Model for the Human Immune System, and Method for Producing the Same - In a method for preparing an animal model for the human immune system in a non-human mammal, human stem cells with hematopoietic potential are transplanted into a non-human mammal. The non-human mammal is conditioned with cell culture supernatant of a culture of human cell lines, cells and/or tissue. The cell culture supernatant is derived from cell lines producing cytokines and other molecular mediators. | 09-04-2008 |
Manja Kircanski, Toronto CA
Patent application number | Description | Published |
---|---|---|
20110130560 | SONICATION CARTRIDGE FOR NUCLEIC ACID EXTRACTION - A cartridge in which sonication is applied to biological matter to disrupt and release nucleic acids from the matter is formed from a cartridge body containing a series of wells connected by fluid passages engineered to prevent backflow, with at least one well containing a sonication window covered by a thin lamina to transmit sonic vibrations from a sonication horn contacting the exterior surface of the window. Fluid transport among the wells is achieved by pressure differentials through the fluid passages, and a succession of functions is performed in the various wells, including disruption, mixing, binding of the released nucleic acids to binding materials, washing, elution, and collection. | 06-02-2011 |
20120046765 | SYSTEM AND METHOD FOR ULTRASONIC TRANSDUCER CONTROL - A system for controlling an ultrasonic transducer utilizes an indication of the relative phase of the voltage on the transducer and the current passing through the transducer to control the relative phase to a value that has been preselected to correspond to resonance of an electromechanical system that includes the ultrasonic transducer. In one example application, the system includes a waveform generator that produces an oscillating signal, and the frequency of the oscillating signal is adjustable under control of the control processor. The control processor adjusts the frequency of the oscillating signal according to a proportional control law at least some of the time, and according to a proportional-integral control law at least some of the time. The control processor may also control the amplitude of the oscillation of the ultrasonic transducer. | 02-23-2012 |